Zvenyslava Maslyak

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies

Tadeusz Robak, Jan A. Burger, Alessandra Tedeschi et al. · American Journal of Hematology · 2018 · 26 citations · Full text

Molecular design, synthesis and anticancer activity of new thiopyrano[2,3-d]thiazoles based on 5-hydroxy-1,4-naphthoquinone (juglone)

Iryna Ivasechko, Andrii Lozynskyi, Julia Senkiv et al. · European Journal of Medicinal Chemistry · 2023 · 25 citations · Full text

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Matthew S. Davids, Asher Chanan‐Khan, Boyd Mudenda et al. · Blood · 2022 · 15 citations

Key Results of International Randomized Open-Label Clinical Study of BCD-020 (rituximab biosimilar candidate) in Patients with B-Cell Non-Hodgkin’s Lymphoma

Kamil Kaplanov, Andrey Zaritskiy, Sergey Alexeev et al. · Blood · 2014 · 12 citations